Soligenix Inc

NASDAQ:SNGX 4:00:00 PM EDT

0.38

-0.02 (-4.25%)

7:19:23 PM EDT: $0.38 0.00 (0.03%)

Market Cap (Intraday)	4.03M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.2 Million
Adjusted EPS	-$0.20

See more estimates

10-Day MA	$0.42
50-Day MA	$0.60
200-Day MA	$0.58

See more pivots

Soligenix Inc Stock, NASDAQ:SNGX

29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540-5919

United States of America

Phone: +1.609.538.8200

Number of Employees: 15

http://www.soligenix.com

Description

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.